Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
‘Agile’ Approach Aims To Accelerate Ridgeback’s COVID-19 Timeline
The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.
Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal
Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.
UK Uses Local Outbreak Data To Target Coronavirus Vaccine Trials
The UK Vaccine Taskforce is helping to troubleshoot for COVID-19 candidates including in clinical trials and manufacturing scale-up.
EU Approves Gilead’s Remdesivir For COVID-19 In Record Time
The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.
Amid Supply Concerns, EU Approves Gilead’s Remdesivir
Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.